Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

ABSTRACT:

Importance

Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation.

Objective

To assess the efficacy of selumetinib, a selective, non-adenosine triphosphate competitive inhibitor of MEK1 and MEK2, in uveal melanoma.

Design, setting, and participants

Randomized, open-label, phase 2 clinical trial comparing selumetinib vs chemotherapy conducted from August 2010 through December 2013 among 120 patients with metastatic uveal melanoma at 15 academic oncology centers in the United States and Canada.

Interventions

One hundred one patients were randomized in a 1:1 ratio to receive selumetinib, 75 mg orally twice daily on a continual basis (n = 50), or chemotherapy (temozolomide, 150 mg/m2 orally d

SUBMITTER: Carvajal RD 

PROVIDER: S-EPMC4249701 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature